Aclasta IV Infusion 5 mg/100 ml

Aclasta IV Infusion is a premium bisphosphonate preparation containing Zoledronic Acid (5 mg/100 ml) manufactured by SANDOZ (A Novartis Division). Priced at ৳38,190.00 per unit, this intravenous infusion is primarily prescribed for osteoporosis management, Paget’s disease, and glucocorticoid-induced bone loss. Its unique mechanism inhibits osteoclast-mediated bone resorption, offering long-term skeletal protection.

The drug is administered annually via a 15-minute IV infusion. Key indications include postmenopausal osteoporosis treatment/prophylaxis, male osteoporosis, and Paget’s disease. Patients must maintain adequate calcium (1,200 mg/day) and vitamin D (800-1,000 IU/day) intake. Storage requires temperatures below 30°C with protection from light and moisture.

Common side effects (＞10% patients) include pyrexia, myalgia, and arthralgia. Serious risks involve hypocalcemia and renal impairment. Drug interactions with aminoglycosides or loop diuretics necessitate careful monitoring. Explore Zoledronic Acid alternatives for comparable therapeutic options.

Contraindicated in pregnancy/lactation, Aclasta demands strict adherence to dosage guidelines. Overdose may cause severe electrolyte imbalances requiring intravenous calcium/magnesium correction. For optimal results, combine with weight-bearing exercises and nutritional support. Learn more about IV Infusion therapies for bone health management.

5 mg/100 ml IV infusion once annually over ≥15 minutes. Contraindicated if creatinine clearance <35 ml/min. Monitor renal function pre-dose. Retreatment in Paget's disease requires biochemical assessment of disease activity.

The most common adverse reactions (greater than 10%) were pyrexia, myalgia, headache, arthralgia, pain in extremity. Other important adverse reactions were flu-like illness, nausea, vomiting, diarrhea, and eye inflammation

Pregnancy Category D: Fetal harm reported. Use effective contraception in women of childbearing potential. Contraindicated during breastfeeding due to unknown excretion in human milk.

Ensure adequate calcium/vitamin D intake. Avoid long-term use without dental exams. Evaluate unexplained thigh/groin pain with X-ray. Strictly control infusion rate/dose in renal impairment.

Not approved for pediatric use. Monitor renal function in elderly. Contraindicated if CrCl <35 ml/min. No dose adjustment needed in hepatic impairment.

Patients who have received doses higher than those recommended should be carefully monitored. Over dosage may cause clinically significant renal impairment, hypocalcemia, hypophosphatemia, and hypomagnesemia. Clinically relevant reductions in serum levels of calcium, phosphorus, and magnesium should be corrected by intravenous administration of calcium gluconate, potassium or sodium phosphate, and magnesium sulfate, respectively. Single doses of Aclasta should not exceed 5 mg and the duration of the intravenous infusion should be no less than 15 minutes.